Organization (Industry)
NovaBridge Biosciences
ClinicalTrials.gov lists NovaBridge Biosciences as lead sponsor of 11 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
20 sections measured, none recorded
This page covers NovaBridge Biosciences and 1 company grouped under it: 11 lead-sponsored trials (0 its own, 11 in the grouped companies) and 1 legal-entity registration (1 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| I-Mab Biopharma US Limited | 11 | 0 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4 | 1 | 2023-03-28 |
Financing and grant events (17)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-10-30 | Other financing | not disclosed | Edgar offerings |
| 2025-08-04 | Other financing | not disclosed | Edgar offerings |
| 2025-07-11 | Other financing | not disclosed | Edgar offerings |
| 2022-03-31 | Other financing | not disclosed | Edgar offerings |
| 2022-01-14 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 17 events.
Latest dated events (21)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-08-04 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-11 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2023-03-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-03-31 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 21 events.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, disease areas, trials by start year as sponsor or collaborator, active development programs, approved assets, sponsor delivery record, journals published in, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.